EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival prediction in glioblastoma: 10-year follow-up from the Dutch Neurosurgery Quality Registry

Jeroen T J M van Dijck, Hilko Ardon, Rutger K Balvers, Eelke M Bos, Lisette Bosscher, H Bart Brouwers, Vincent K Y Ho, Koos Hovinga, Lesley Kwee, Mark Ter Laan, Rob J A Nabuurs, Pierre A J T Robe und 8 weitere

Journal of Neuro-Oncology · 2025-09 · 174 (3) · 753-764

DOI: 10.1007/s11060-025-05080-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 23.05.2025. Verfasst von Jeroen T J M van Dijck und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Haaglanden Medical Centre, The Hague, The Netherlands. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Neurosurgical Procedures. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Glioblastoma is the most common and treatment-resistant primary malignant brain tumor, with high morbidity and mortality despite standard treatment protocols. This study aims to evaluate survival and prognostic factors, and introduce two pragmatic prognostic models to inform individualized, patient-centered decision-making, using a large Dutch registry.

Methods

We analyzed a prospective cohort of 7621 patients (2012–2022) in 12 Dutch centers via the Dutch Quality Registry Neurosurgery. Univariate analysis of prognostic factors, Kaplan–Meier survival curves, and funnel plots comparing center performance (30-day and 2-year mortality) were conducted. Two prognostic models using multivariate Cox regression were developed.

Results

Glioblastoma incidence was 3.9/100.000 in The Netherlands. Overall, 30-day mortality was 5.1% and 2-year survival 17.8%. Overall median survival was 10.4 months, with 4.6 months after biopsy and 12.9 months post-resection. Poorer survival correlated with older age, higher ASA classification, lower Karnofsky Performance Status, biopsy over resection (HR 0.49, 95% CI 0.47–0.52), and postoperative complications (HR 1.57 95% CI 1.39–1.79). MGMT promotor methylation (HR 0.58, 95% CI 0.53–0.63) and adjuvant treatment were linked to lower mortality. Treatment variation and outcomes were within expected ranges; surgical volume did not affect survival. The prognostic models had C-indices of 0.704 (6-month) and 0.721 (2-year).

Conclusion

Surgical resection and adjuvant therapy improved survival, but prognosis remained poor. Age, premorbid condition, treatment and molecular markers influenced survival. Center variations were within expected range, and higher surgical volume did not improve outcomes. The developed prognostic models could potentially inform clinicians, pending external validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsNeurosurgical ProceduresHumansMaleFemaleRegistriesMiddle AgedNetherlandsFollow-Up StudiesAgedPrognosisAdultProspective StudiesSurvival RateYoung AdultAged, 80 and over

Stichwörter der Autor:innen

GlioblastomaPatient outcomePrognostic modelSurvival

Autor:innen und Institutionen

  • Department of Neurosurgery, Haaglanden Medical Centre, The Hague, The Netherlands.
  • Department of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Neurosurgery, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands.
  • Department of Neurosurgery, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • Department of Neurosurgery, Isala, Zwolle, The Netherlands.
  • Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

Zitieren

APA

van Dijck, J. T. J. M., Ardon, H., Balvers, R. K., Bos, E. M., Bosscher, L., Brouwers, H. B., Ho, V. K. Y., Hovinga, K., Kwee, L., Ter Laan, M., Nabuurs, R. J. A., Robe, P. A. J. T., van Geest, S., van der Veer, O., Verburg, N., Wagemakers, M., de Witt Hamer, P. C., Rodriguez Girondo, M., Nandoe Tewarie, R. D. S., & Quality Registry Neuro Surgery glioblastoma working group from the Dutch Society of Neurosurgery (2025). Survival prediction in glioblastoma: 10-year follow-up from the Dutch Neurosurgery Quality Registry. Journal of Neuro-Oncology, 174(3), 753-764. https://doi.org/10.1007/s11060-025-05080-3

Vancouver

van Dijck JTJM, Ardon H, Balvers RK, Bos EM, Bosscher L, Brouwers HB, et al. Survival prediction in glioblastoma: 10-year follow-up from the Dutch Neurosurgery Quality Registry. Journal of Neuro-Oncology. 2025;174(3):753-764. doi:10.1007/s11060-025-05080-3

BibTeX
@article{vanDijck2025,
  author = {van Dijck, Jeroen T J M and Ardon, Hilko and Balvers, Rutger K and Bos, Eelke M and Bosscher, Lisette and Brouwers, H Bart and Ho, Vincent K Y and Hovinga, Koos and Kwee, Lesley and Ter Laan, Mark and Nabuurs, Rob J A and Robe, Pierre A J T and van Geest, Sarita and van der Veer, Olivier and Verburg, Niels and Wagemakers, Michiel and de Witt Hamer, Philip C and Rodriguez Girondo, Mar and Nandoe Tewarie, Rishi D S and Quality Registry Neuro Surgery glioblastoma working group from the Dutch Society of Neurosurgery, Quality Registry Neuro Surgery glioblastoma working group from the Dutch Society of Neurosurgery},
  title = {Survival prediction in glioblastoma: 10-year follow-up from the Dutch Neurosurgery Quality Registry},
  journal = {Journal of Neuro-Oncology},
  year = {2025},
  volume = {174},
  number = {3},
  pages = {753--764},
  doi = {10.1007/s11060-025-05080-3}
}
Kostenlos starten →